A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma
Information source: NIH AIDS Clinical Trials Information Service
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Sarcoma, Kaposi; HIV Infections
Intervention: Doxorubicin hydrochloride (liposomal) (Drug); Bleomycin sulfate (Drug); Vincristine sulfate (Drug); Doxorubicin hydrochloride (Drug)
Phase: Phase 3
Status: Active, not recruiting
Sponsored by: Sequus Pharmaceuticals
To determine the efficacy of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the
treatment of severe AIDS-related Kaposi's sarcoma (KS) by comparison with the established
therapy ABV: Adriamycin (doxorubicin)/bleomycin/vincristine. To evaluate the safety and
tolerance of DOX-SL compared to ABV in a population of AIDS patients with severe KS.
Official title: Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Adriamycin, Bleomycin, and Vincristine (ABV) in the Treatment of Severe AIDS-Related Kaposi's Sarcoma
Study design: Treatment, Parallel Assignment, Safety Study
Patients are randomized to receive either DOX-SL or the ABV combination. Infusions are given
on day 1 and every 2 weeks for a total of six cycles. Kaposi's sarcoma lesions are evaluated
prior to every cycle, at the end of the last treatment cycle, and 4 weeks following the end
of the last treatment. Patients must agree to have one or more representative KS lesions
Minimum age: 18 Years.
Maximum age: N/A.
- Prophylaxis for PCP, cryptococcal, and herpes infections, and antiretroviral therapy
(e. g., AZT, ddC, ddI) provided these doses have been stable for at least 1 month.
- Therapy for tuberculosis, fungal, and herpes infections except with potentially
- Foscarnet for new episodes of cytomegalovirus infection.
- Colony-stimulating factors and erythropoietin.
Patients must have:
- Biopsy-proven, progressive, AIDS-related Kaposi's sarcoma, with any of the following:
- At least 25 mucocutaneous lesions.
- Ten or more new lesions in the prior month.
- Documented visceral disease with at least two accessible cutaneous lesions.
- Two accessible cutaneous lesions with edema.
- Documented anti-HIV antibody.
- No active opportunistic infection with mycobacteria, cytomegalovirus, toxoplasma,
Pneumocystis carinii, or other microorganisms (if under treatment with myelotoxic
- Life expectancy > 4 months.
- Patients who respond to therapy on this protocol, as well as those who fail the ABV
combination, are eligible to enter the Liposome Technology open trial using DOX-SL
Patients with the following symptoms or conditions are excluded:
- Clinically significant cardiac, hepatic, or renal disease.
- Peripheral neuropathy, signs of moderate to severe sensory loss, or moderate to marked
- Inability to comply with the study.
- Other cytotoxic chemotherapy.
Patients with the following prior conditions are excluded:
- Prior neoplasms treated with extensive chemotherapy that, in the investigator's
opinion, has led to irreversibly compromised bone marrow function.
- History of idiosyncratic or allergic reaction to bleomycin or vincristine.
- Prior anthracycline therapy.
- Cytotoxic chemotherapy or interferon treatment within the past 4 weeks.
- Radiation or electron beam therapy within the past 3 weeks.
Locations and Contacts
UCSF - San Francisco Gen Hosp, San Francisco, California 94110, United States
Kaiser Permanente Med Ctr, San Francisco, California 94115, United States
Dr Becky Miller, Los Angeles, California 90048, United States
Pacific Oaks Med Group, Beverly Hills, California 90211, United States
Hematology - Oncology Med Group of San Fernando Valley, Encino, California 91436, United States
Apogee Med Group, San Diego, California 92103, United States
San Francisco Veterans Administration Med Ctr, San Francisco, California 94121, United States
UCSF, San Francisco, California 94117, United States
UCSF, San Francisco, California 941430324, United States
Pacific Oaks Med Group, Sherman Oaks, California 91403, United States
East Bay AIDS Ctr, Berkeley, California 94705, United States
Dr Mahmoud Mustafa, Washington, District of Columbia 20037, United States
Univ of Miami School of Medicine, Miami, Florida 33136, United States
H Lee Moffit Cancer Ctr and Research Institute, Tampa, Florida 33612, United States
American Med Research Institute, Atlanta, Georgia 30329, United States
Infectious Disease Rsch Consortium of GA / SE Clin Resources, Atlanta, Georgia 30345, United States
Rush Presbyterian Med College, Chicago, Illinois 60612, United States
Illinois Masonic Med Ctr / The Cancer Ctr, Chicago, Illinois 60657, United States
Northwestern Med Faculty Foundation, Chicago, Illinois 60611, United States
Henry Ford Hosp, Detroit, Michigan 48202, United States
Washington Univ, St. Louis, Missouri 63108, United States
Roswell Park Cancer Institute, Buffalo, New York 14263, United States
New York Univ Med Ctr, New York, New York 10016, United States
Saint Luke's - Roosevelt Hosp Ctr, New York, New York 10023, United States
Saint Vincent's Hosp and Med Ctr, New York, New York 10011, United States
Graduate Hosp / Tuttleman Cancer Ctr, Philadelphia, Pennsylvania 19146, United States
Comprehensive Care Ctr, Dallas, Texas 75235, United States
Baylor College of Medicine, Houston, Texas 77030, United States
Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC, Ross ME. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1996 Aug;14(8):2353-64.
Last updated: June 23, 2005